AC Immune, Ltd. has entered into an exclusive global license agreement and research collaboration with Genentech for the development of anti-beta-amyloid antibodies for the potential treatment of Alzheimer’s Disease (AD) and other human diseases. Beta-amyloid is an important target for disease-modification of AD and AC Immune has developed conformation-specific antibodies against this protein generated by its SupraAntigen Technology. Under the terms of this agreement, Genentech will m...